^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    VAX014 intratumoral

    i
    Other names: VAX014 intratumoral, VAX014 intralesional
    Associations

    News

    Trials
    Company:
    Vaxiion Therap
    Drug class:
    α3β1 integrin inhibitor, α5β1 integrin inhibitor
    Related drugs:
    Associations

    News

    Trials
    7ms
    VX0120: Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=43, Recruiting, Vaxiion Therapeutics | N=32 --> 43 | Trial completion date: May 2026 --> Nov 2026 | Trial primary completion date: May 2026 --> Aug 2026
    Enrollment change • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • VAX014 intratumoral
    1year
    VAX014 Activates Tumor-Intrinsic STING and RIG-I to Promote the Development of Antitumor Immunity. (PubMed, Mol Cancer Ther)
    These collective findings differentiate VAX014 from OVs by elucidating the ability of this agent to elicit antitumor activity in STING- and/or RIG-I-positive solid tumors and provide evidence that STING/RIG-I agonism is part of VAX014's mechanism of action. Taken together, this work supports the ongoing clinical investigation of VAX014 treatment as an alternative to OV therapy in patients with solid tumors.
    Journal • IO biomarker
    |
    STING (stimulator of interferon response cGAMP interactor 1)
    |
    VAX014 intratumoral
    2years
    Phase 1 Study of Intratumoral Administration of VAX014 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=32, Recruiting, Vaxiion Therapeutics
    Trial completion date • Trial primary completion date • Metastases
    |
    VAX014 intratumoral
    over2years
    Phase 1 Study of Intratumoral Administration of VAX014 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=32, Recruiting, Vaxiion Therapeutics | Not yet recruiting --> Recruiting | Initiation date: Jul 2023 --> Nov 2023
    Enrollment open • Trial initiation date • Metastases
    |
    VAX014 intratumoral
    over2years
    VAX014 as a novel oncolytic agent for STING and RIG-I-positive solid tumors (SITC 2023)
    Conclusions VAX014 activates both the murine STING and RIG-I pathways and the presence of tumor-intrinsic STING and/or RIG-I leads to optimal antitumor activity of VAX014 following i. t. administration. This unique mechanism pairs STING and RIG-I agonism and subsequent Type I IFN production with oncolysis-mediated availability of tumor antigens, which together, may lead to better antitumor T cell priming.
    PD(L)-1 Biomarker • IO biomarker
    |
    STING (stimulator of interferon response cGAMP interactor 1)
    |
    VAX014 intratumoral
    over2years
    Phase 1 Study of Intratumoral Administration of VAX014 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=32, Not yet recruiting, Vaxiion Therapeutics
    New P1 trial • Metastases
    |
    VAX014 intratumoral
    over2years
    Intralesional administration of VAX014 facilitates in situ immunization and potentiates immune checkpoint blockade in immunologically cold tumors. (PubMed, J Immunother Cancer)
    Intratumoral administration of VAX014 stimulates local immune activation and robust systemic antitumor lymphocytic responses. Combination with systemic ICB deepens systemic antitumor responses to mediate clearance of injected and distal non-injected tumors.
    Journal • Checkpoint inhibition • Checkpoint block
    |
    CD8 (cluster of differentiation 8)
    |
    VAX014 intratumoral